| Autor: |
Gledys Reynaldo, Leyanis Rodríguez, Roberto Menéndez, Joaquín Solazábal, Daniel Amaro, María de los A. Becquer, Yamila Colom, Haydee Gil, Juan C. Polo, Gilberto Castañeda, Braulio Jiménez-Vélez, Jorge Duconge, Eduardo M. Fernández-Sánchez |
| Jazyk: |
English<br />Spanish; Castilian |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Journal of Pharmacy & Pharmacognosy Research, Vol 6, Iss 3, Pp 179-190 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
0719-4250 |
| Popis: |
Context: The recombinant human erythropoietin (rHuEPO) stimulates the erythropoiesis process. Because this glycoprotein has a short half-life, it needs to be administrated two to three times a week. One of the technics to solve this issue is the PEGgilation. Aims: To evaluate the pharmacokinetics (PK) and pharmacodynamics of two new branched PEGylated erythropoietins (i.e., an asymmetric 32 kDa-PEG2-rHuEPO and a symmetric 40 kDa-PEG2-rHuEPO molecule) compared to non-PEGylated ior®EPOCIM and MIRCERA®. Methods: Serum concentrations of both PEGylated and non-PEGylated erythropoietins were measured at various time points in order to determine PK parameters using non-compartmental analysis approach. The reticulocyte (%), erythrocyte count and hemoglobin levels were ascertained in order to compare the effect of these molecules after administrating a single intravenous dose (10 μg/kg) of each product in male New Zealand rabbits. Results: Both branched PEGylated erythropoietin forms exhibited half-lives that were significantly longer than ior®EPOCIM (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
